Review: Complement receptor 1 therapeutics for prevention of immune hemolysis

Immunohematology

Volumn 21, Issue 3, 2005, Pages 109-118

  Yazdanbakhsh, Karina ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

Autoimmune hemolytic anemia; CD4 +CD25+; Complement; Complement receptor 1; Immune hemolysis; Inhibitors; LHR; Regulatory T cells; sCR1; Transfusion medicine

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR; GENE PRODUCT; GLYCOPROTEIN;

ALTERNATIVE RNA SPLICING; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; BLOOD TRANSFUSION REACTION; CELL SURVIVAL; CELL TYPE; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DISEASE ASSOCIATION; ERYTHROCYTE TRANSFUSION; HEMOLYSIS; HUMAN; HUMAN CELL; IN VIVO STUDY; INFECTION PREVENTION; INNATE IMMUNITY; KNOCKOUT GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANIMALS; DISEASE MODELS, ANIMAL; HEMOLYSIS; HUMANS; MICE; MICE, KNOCKOUT; RECEPTORS, COMPLEMENT 3B; RECOMBINANT PROTEINS;

EID: 25844516435     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Volanakis JE, Frank MM. The human complement system in health and disease. New York: Marcel Dekker, Inc., 1998.
2. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004;5:981-6.
3. O'Shea JJ, Brown EJ, Gaither TA, Takahashi T, Frank MM. Tumor-promoting phorbol esters induce rapid internalization of the C3b receptor via a cytoskeleton-dependent mechanism. J Immunol 1985;135:1325-30.
4. Hugli TE, Muller-Eberhard HJ. Anaphylatoxins: C3a and C5a. Adv Immunol 1978;26:1-53.
5. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atklnson JP. Control of the complement system. Adv Immunol 1996;61:201-83.
6. Petz LD, Garratty G. Immune hemolytic anemias. 2nd ed. Philadelphia: Churchill Livingstone, 2004.
7. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990;30: 583-90.
8. Sazama K. Transfusion errors: scope of the problem, consequences, and solutions. Curr Hematol Rep 2003;2:518-21.
9. Schreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest 1972; 51:583-9.
10. Mollison PL, Engelfriet CP, Contreras M. Blood transfusion in clinical medicine. 10th ed. Oxford, England: Blackwell Science, 1997.
11. Fischer JT, Petz LD, Garratty G, Cooper NR. Correlations between quantitative assay of red cell-bound C3, serologic reactions, and hemolytic anemia. Blood 1974;44:359-73.
12. Hourcade D, Liszewski MK, Krych-Goldberg M, Atkinson JP. Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1. Immunopharmacology 2000;49:103-16.
13. Iida K, Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J Exp Med 1981;153:1138-50.
14. Fearon DT. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci USA 1979;76:5867-71.
15. Ross GD. Complement receptor type 1. Curr Top Microbiol Immunol 1992;178:31-44.
16. Klickstein LB, Barbashov SF, Liu T, Jack RM, Nicholson-Weller A. Complement receptor type 1 (CR1, CD35) is a receptor for C1q. Immunity 1997;7:345-55.
17. Ghiran I, Barbashov SF, Klickstein LB, et al. Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J Exp Med 2000;192:1797-1808.
18. Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989;46:183-219.
19. Nelson RA. The immune adherence phenomenon: an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis. Science 1953;118:733-7.
20. Cooper NR. Immune adherence by the fourth component of complement. Science 1969;165: 396-8.
21. Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med 1980;152:20-30.
22. Paccaud JP, Carpentier JL, Schifferli JA. Direct evidence for the clustered nature of complement receptors type 1 on the erythrocyte membrane. J Immunol 1988;141:3889-94.
23. Cornacoff JB, Hebert LA, Smead WL, et al. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest 1983;71:236-47.
24. Gigli I, Nelson RA, Jr. Complement dependent immune phagocytosis. I. Requirements for C′1, C′4, C′2, C′3. Exp Cell Res 1968;51:45-67.
25. Brown EJ. Complement receptors and phagocytosis. Curr Opin Immunol 1991;3:76-82.
26. Molina H, Holers VM, Li B, et al. Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. Proc Natl Acad Sci USA 1996;93:3357-61.
27. Kozono Y, Abe R, Kozono H, et al. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. J Immunol 1998;160:1565-72.
28. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Ann Rev Immunol 2000;18:393-422.
29. Gray D, Kumararatne DS, Lortan J, Khan M, MacLennan IC. Relation of intra-splenic migration of marginal zone B cells to antigen localization on follicular dendritic cells. Immunology 1984;52: 659-69.
30. Enriquez-Rincon F, Andrew E, Parkhouse RM, Klaus GG. Suppression of follicular trapping of antigen-antibody complexes in mice treated with anti-IgM or anti-IgD antibodies from birth. Immunology 1984;53:713-9.
31. Pozdnyakova O, Guttormsen HK, Lalani FN, Carroll MC, Kasper DL. Impaired antibody response to group B streptococcal type III capsular polysaccharide in C3- and complement receptor 2-deficient mice. J Immunol 2003;170:84-90.
32. Brown JC, Harris G, Papamichail M, Sljivic VS, Holborow EJ. The localization of aggregated human-globulin in the spleens of normal mice. Immunology 1973;24:955-68.
33. Kroese FG, Wubbena AS, Nieuwenhuis P. Germinal centre formation and follicular antigen trapping in the spleen of lethally X-irradiated and reconstituted rats. Immunology 1986;57:99-104.
34. Van den Berg TK, Yoshida K, Dijkstra CD. Mechanism of immune complex trapping by follicular dendritic cells. Curr Top Microbiol Immunol 1995;201:49-67.
35. Fischer MB, Ma M, Hsu NC, Carroll MC. Local synthesis of C3 within the splenic lymphoid compartment can reconstitute the impaired immune response in C3-deficient mice. J Immunol 1998;160:2619-25.
36. Zandvoort A, Timens W. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin Exp Immunol 2002;130:4-11.
37. Wilson JG, Tedder TF, Fearon DT. Characterization of human T lymphocytes that express the C3b receptor. J Immunol 1983;131:684-9.
38. Yaskanin DD, Thompson LF, Waxman FJ. Distribution and quantitative expression of the complement receptor type 1 (CR1) on human peripheral blood T lymphocytes. Cell Immunol 1992;142:159-176.
39. Rodgaard A, Thomsen BS, Bendixen G, Bendtzen K. Increased expression of complement receptor type 1 (CR1, CD35) on human peripheral blood T lymphocytes after polyclonal activation in vitro. Immunol Res 1995;14:69-76.
40. Mouhoub A, Delibrias CC, Fischer E, Boyer V, Kazatchkine MD. Ligation of CR1 (C3b receptor, CD35) on CD4+ T lymphocytes enhances viral replication in HIV-infected cells. Clin Exp Immunol 1996;106:297-303.
41. Kinoshita T, Takeda J, Hong K, et al. Monoclonal antibodies to mouse complement receptor type 1 (CR1). Their use in a distribution study showing that mouse erythrocytes and platelets are CR1-negative. J Immunol 1988;140:3066-72.
42. Cockburn IA, Mackinnon MJ, O'Donnell A, et al. A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria. Proc Natl Acad Sci USA 2004;101:272-7.
43. Cohen JH, Atkinson JP, Klickstein LB, et al. The C3b/C4b receptor (CR1, CD35) on erythrocytes: methods for study of the polymorphisms. Mol Immunol 1999;36:819-25.
44. Klickstein LB, Wong WW, Smith JA, et al. Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med 1987; 165:1095-1112.
45. Klickstein LB, Bartow TJ, Miletic V, et al. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1,CD35) by deletion mutagenesis. J Exp Med 1988;168: 1699-1717.
46. Fingeroth JD, Benedict MA, Levy DN, Strominger JL. Identification of murine complement receptor type 2. Proc Natl Acad Sci USA 1989;86:242-6.
47. Molina H, Kinoshita T, Inoue K, Carel JC, Holers VM. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2. J Immunol 1990;145:2974-83.
48. Kurtz CB, O'Toole E, Christensen SM, Weis JH. The murine complement receptor gene family. IV Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J Immunol 1990;144:3581-91.
49. Makrides SC. Therapeutic inhibition of the complement system. Pharmacol Rev 1998;50:59-87.
50. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990;249:146-51.
51. Perry GJ, Eisenberg PR, Zimmerman JI, Levin J. Phase I safety trial of soluble complement receptor 1 (TP10) in acute myocardial infarction. J Am Coll Cardiol 1998;31:411A.
52. Zamora MR, Davis RD, Keshavjee SH, et al. Complement inhibition attenuates human lung transplant reperfusion injury: a multicenter trial. Chest 1999;116:46S.
53. Zimmerman JL, Dellinger RP, Straube RC, Levin JL. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med 2000;28:3149-54.
54. Yazdanbakhsh K, Kang S, Tamasauskas D, Sung D, Scaradavou A. Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy. Blood 2003;101:5046-52.
55. Yazdanbakhsh K, Scaradavou A. CR1-based inhibitors for prevention of complement-mediated immune hemolysis. Drug Design and Perspectives 2004;17(5):314-20.
56. Krych M, Clemenza L, Howdeshell D, et al. Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. J Biol Chem 1994;269:13273-8.
57. Krych M, Hauhart R, Atkinson JP. Structure-function analysis of the active sites of complement receptor type 1. J Biol Chem 1998;273:8623-9.
58. Krych-Goldberg M, Hauhart RE, Subramanian VB, et al. Decay accelerating activity of complement receptor type 1 (CD35). Two active sites are required for dissociating C5 convertases. J Biol Chem 1999;274:31160-8.
59. Mqadmi A, Abdullah Y, Yazdanbakhsh K. Characterization of complement receptor 1 domains for prevention of complement-mediated red cell destruction. Transfusion 2005;45(2):234-44.
60. Scesney SM, Makrides SC, Gosselin ML, et al. A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway. Eur J Immunol 1996;26:1729-35.
61. Mulligan MS, Warner RL, Rittershaus CW, et al. Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties. J Immunol 1999;162:4952-9.
62. Makrides SC, Scesney SM, Ford PJ, et al. Cell surface expression of the C3b/C4b receptor (CR1) protects Chinese hamster ovary cells from lysis by human complement. J Biol Chem 1992;267:24754-61.
63. Krych M, Hourcade D, Atkinson JP. Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc Natl Acad Sci USA 1991;88:4353-7.
64. Reilly BD, Makrides SC, Ford PJ, Marsh HC, Jr., Mold C. Quantitative analysis of C4b dimer binding to distinct sites on the C3b/C4b receptor (CR1). J Biol Chem 1994;269:7696-7701.
65. Morgan BP, Harris CL. Complement therapeutics; history and current progress. Mol Immunol 2003;40:159-70.
66. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000;76:227-324.
67. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-66.
68. Botto M, Dell'Agnola C, Bygrave AE, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nature Genet 1998;19:56-9.
69. Miyakawa Y, Yamada A, Kosaka K, et al. Defective immune-adherence (C3b) receptor on erythrocytes from patients with systemic lupus erythematosus. Lancet 1981;2:493-7.
70. Wilson JG, Ratnoff WD, Schur PH, Fearon DT. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum 1986;29:739-47.
71. Levy E, Ambrus J, Kahl L, et al. T lymphocyte expression of complement receptor 2 (CR2/ CD21): a role in adhesive cell-cell interactions and dysregulation in a patient with systemic lupus erythematosus (SLE). Clin Exp Immunol 1992;90: 235-44.
72. Marquart HV, Svendsen A, Rasmussen JM, et al. Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 1995;101:60-5.
73. Emancipator SN, Iida K, Nussenzweig V, Gallo GR. Monoclonal antibodies to human complement receptor (CR1) detect defects in glomerular diseases. Clin Immunol Immunopathol 1983;27: 170-5.
74. Kazatchkine MD, Fearon DT, Appay MD, Mandet C, Bariety J. Immunohistochemical study of the human glomerular C3b receptor in normal kidney and in seventy-five cases of renal diseases: loss of C3b receptor antigen in focal hyalinosis and in proliferative nephritis of systemic lupus erythematosus. J Clin Invest 1982;69:900-12.
75. Jones J, Laffafian I, Cooper AM, Williams BD, Morgan BP. Expression of complement regulatory molecules and other surface markers on neutrophils from synovial fluid and blood of patients with rheumatoid arthritis. Br J Rheumatol 1994;33:707-12.
76. Thomsen BS, Oxholm P, Manthorpe R, Nielsen H. Complement C3b receptors on erythrocytes, circulating immune complexes, and complement C3 split products in patients with primary Sjogren's syndrome. Arthritis Rheum 1986;29:857-62.
77. Ruuska PE, Ikaheimo I, Silvennoinen-Kassinen S, Kaar ML, Tiilikainen A. Normal C3b receptor (CR1) genomic polymorphism in patients with insulin-dependent diabetes mellitus (IDDM): is the low erythrocyte CR1 expression an acquired phenomenon? Clin Exp Immunol 1992;89:18-21.
78. Takahashi K, Kozono Y, Waldschmidt TJ, et al. Mouse complement receptors type 1 (CR1;CD35) and type 2 (CR2;CD21): expression on normal B cell subpopulations and decreased levels during the development of autoimmunity in MRL/lpr mice. J Immunol 1997;159:1557-69.
79. Prodeus AP, Goerg S, Shen LM, et al. A critical role for complement in maintenance of self-tolerance. Immunity 1998;9:721-31.
80. Adams EM, Brown MC, Nunge M, Krych M, Atkinson JP. Contribution of the repeating domains of membrane cofactor protein (CD46) of the complement system to ligand binding and cofactor activity. J Immunol 1991;147:3005-11.
81. Kemper C, Chan AC, Green JM, et al. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature 2003;421: 388-92.
82. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.
83. Thompson C, Powrie F. Regulatory T cells. Curr Opin Pharmacol 2004;4:408-14.
84. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-64.
85. Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol 2000;18:423-49.
86. Kuniyasu Y, Takahashi T, Itoh M, et al. Naturally anergic and suppressive CD25(+)CD4(+) T cells as a functionally and phenotypically distinct immunoregulatory T cell subpopulation. Int Immunol 2000;12:1145-55.
87. Lehmann J, Huehn J, de la RM, et al. Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25-regulatory T cells. Proc Natl Acad Sci USA 2002;99:13031-6.
88. Szanya V, Ermann J, Taylor C, Holness C, Fathman CG. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J Immunol 2002;169:2461-5.
89. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000;164: 183-90.
90. Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998;10: 1969-80.
91. Jonuleit H, Schmitt E, Stassen M, et al. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001;193:1285-94.
92. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001;193:1303-10.
93. Levings MK, Sangregorio R, Roncarolo MG. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001;193:1295-1302.
94. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25 high regulatory cells in human peripheral blood. J Immunol 2001;167:1245-53.
95. Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 2001;182:58-67.
96. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-96.
97. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001;167: 1137-40.
98. Caramalho I, Lopes-Carvalho T, Ostler D, et al. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003;197:403-11.
99. Mills KH. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004; 4:841-55.
100. Araujo MI, Hoppe BS, Medeiros M, Jr., Carvalho EM. Schistosoma mansoni infection modulates the immune response against allergic and autoimmune diseases. Mem Inst Oswaldo Cruz 2004; 99:27-32.
101. Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344:1140-44.
102. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 2002;69:258-71.
103. Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2001;2:797-801.
104. Kalli KR, Hsu PH, Bartow TJ, et al. Mapping of the C3b-binding site of CR1 and construction of a (CR1)2- F(ab′)2 chimeric complement inhibitor. J Exp Med 1991;174:1451-60.